Analgesic Comparative Trials Urged; Placebo Still Standard for Approval
FDA should encourage sponsors to conduct comparisons between standard analgesic therapies and newer agents, Arthritis Committee guest Mitchell Max, MD, National Institutes of Health, suggested
You may also be interested in...
Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said
Analgesic acute pain trails should assess long-term safety and multiple doses, members of FDA's Arthritis Advisory Committee suggested July 30
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011